ER7 Fundamental Analysis - ERAMET

Fundamental Rating

Taking everything into account, ER7 scores 2 out of 10 in our fundamental rating. ER7 was compared to 42 industry peers in the Metals & Mining industry. ER7 has a bad profitability rating. Also its financial health evaluation is rather negative. ER7 is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ER7 has reported negative net income.
ER7 had a negative operating cash flow in the past year.
ER7 had positive earnings in 4 of the past 5 years.
ER7 had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

The Return On Assets of ER7 (-1.58%) is worse than 66.67% of its industry peers.
Looking at the Return On Equity, with a value of -9.29%, ER7 is doing worse than 76.19% of the companies in the same industry.
The Return On Invested Capital of ER7 (0.80%) is worse than 71.43% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ER7 is in line with the industry average of 7.48%.
The 3 year average ROIC (7.29%) for ER7 is well above the current ROIC(0.80%). The reason for the recent decline needs to be investigated.

		Industry Rank	Sector Rank
ROA	-1.58%
ROE	-9.29%
ROIC	0.8%

ROA(3y)4.1%

ROA(5y)1.33%

ROE(3y)16.44%

ROE(5y)-1.91%

ROIC(3y)7.29%

ROIC(5y)7.73%

1.3 Margins

In the last couple of years the Profit Margin of ER7 has declined.
With a Operating Margin value of 1.91%, ER7 is not doing good in the industry: 64.29% of the companies in the same industry are doing better.
ER7's Operating Margin has declined in the last couple of years.
ER7's Gross Margin of 68.15% is amongst the best of the industry. ER7 outperforms 90.48% of its industry peers.
In the last couple of years the Gross Margin of ER7 has grown nicely.

		Industry Rank	Sector Rank
OM	1.91%
PM (TTM)	N/A
GM	68.15%

OM growth 3Y-46.5%

OM growth 5Y-18.83%

PM growth 3Y-61.12%

PM growth 5YN/A

GM growth 3Y-3.21%

GM growth 5Y23.96%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ER7 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for ER7 has been increased compared to 1 year ago.
ER7 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ER7 has been reduced compared to a year ago.

2.2 Solvency

ER7 has an Altman-Z score of 1.19. This is a bad value and indicates that ER7 is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.19, ER7 is doing worse than 73.81% of the companies in the same industry.
ER7 has a Debt/Equity ratio of 2.03. This is a high value indicating a heavy dependency on external financing.
ER7's Debt to Equity ratio of 2.03 is on the low side compared to the rest of the industry. ER7 is outperformed by 90.48% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.03
Debt/FCF	N/A
Altman-Z	1.19

ROIC/WACC0.08

WACC9.51%

2.3 Liquidity

ER7 has a Current Ratio of 1.54. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
ER7's Current ratio of 1.54 is on the low side compared to the rest of the industry. ER7 is outperformed by 73.81% of its industry peers.
ER7 has a Quick Ratio of 1.06. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
ER7's Quick ratio of 1.06 is on the low side compared to the rest of the industry. ER7 is outperformed by 64.29% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.54
Quick Ratio	1.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ER7 have decreased strongly by -219.63% in the last year.
The earnings per share for ER7 have been decreasing by -64.00% on average. This is quite bad
ER7 shows a decrease in Revenue. In the last year, the revenue decreased by -6.91%.
ER7 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.39% yearly.

EPS 1Y (TTM)-219.63%

EPS 3Y-64%

EPS 5YN/A

EPS Q2Q%-268.75%

Revenue 1Y (TTM)-6.91%

Revenue growth 3Y-7.18%

Revenue growth 5Y-4.39%

Sales Q2Q%-3.31%

3.2 Future

ER7 is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -44.51% yearly.
The Revenue is expected to grow by 7.00% on average over the next years.

EPS Next Y-340.43%

EPS Next 2Y-74.62%

EPS Next 3Y-44.51%

EPS Next 5YN/A

Revenue Next Year-0.95%

Revenue Next 2Y5.78%

Revenue Next 3Y7%

Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ER7 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ER7 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as ER7.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	19.24

4.3 Compensation for Growth

A cheap valuation may be justified as ER7's earnings are expected to decrease with -44.51% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-74.62%

EPS Next 3Y-44.51%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ER7 has a Yearly Dividend Yield of 1.98%.
ER7's Dividend Yield is a higher than the industry average which is at 1.66.
Compared to an average S&P500 Dividend Yield of 1.89, ER7 has a dividend comparable with the average S&P500 company.

		Industry Rank	Sector Rank
Dividend Yield	1.98%

5.2 History

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years1

5.3 Sustainability

The earnings of ER7 are negative and hence is the payout ratio. ER7 will probably not be able to sustain this dividend level.

DP-44.33%

EPS Next 2Y-74.62%

EPS Next 3Y-44.51%

More info and screens

Find the best dividend stocks

Show peers with best dividend

ERAMET

FRA:ER7 (1/16/2026, 7:00:00 PM)

80.6

-4.45 (-5.23%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryMetals & Mining

Earnings (Last)10-30 2025-10-30

Earnings (Next)02-17 2026-02-17/amc

Inst Owners15.34%

Inst Owner ChangeN/A

Ins Owners0.17%

Ins Owner ChangeN/A

Market Cap2.32B

Revenue(TTM)2.88B

Net Income(TTM)-97.00M

Analysts52.73

Price Target53.14 (-34.07%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	1.98%

Yearly Dividend1.51

Dividend Growth(5Y)N/A

DP-44.33%

Div Incr Years0

Div Non Decr Years1

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)1.94%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-2336.59%

EPS NY rev (3m)-30.76%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-3.86%

Revenue NY rev (3m)-6.63%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.8
P/FCF	N/A
P/OCF	N/A
P/B	2.22
P/tB	4.29
EV/EBITDA	19.24

EPS(TTM)-3.42

EYN/A

EPS(NY)-4.4

Fwd EYN/A

FCF(TTM)-25.76

FCFYN/A

OCF(TTM)-4.59

OCFYN/A

SpS100.31

BVpS36.3

TBVpS18.78

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.58%
ROE	-9.29%
ROCE	1.16%
ROIC	0.8%
ROICexc	0.95%
ROICexgc	1.09%
OM	1.91%
PM (TTM)	N/A
GM	68.15%
FCFM	N/A

ROA(3y)4.1%

ROA(5y)1.33%

ROE(3y)16.44%

ROE(5y)-1.91%

ROIC(3y)7.29%

ROIC(5y)7.73%

ROICexc(3y)10.98%

ROICexc(5y)11.38%

ROICexgc(3y)12.91%

ROICexgc(5y)13.43%

ROCE(3y)10.76%

ROCE(5y)11.32%

ROICexgc growth 3Y-56.22%

ROICexgc growth 5Y-25.38%

ROICexc growth 3Y-55.33%

ROICexc growth 5Y-24.94%

OM growth 3Y-46.5%

OM growth 5Y-18.83%

PM growth 3Y-61.12%

PM growth 5YN/A

GM growth 3Y-3.21%

GM growth 5Y23.96%

F-Score2

Asset Turnover0.47

Health

		Industry Rank	Sector Rank
Debt/Equity	2.03
Debt/FCF	N/A
Debt/EBITDA	10.29
Cap/Depr	403.31%
Cap/Sales	21.11%
Interest Coverage	0.34
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.54
Quick Ratio	1.06
Altman-Z	1.19

F-Score2

WACC9.51%

ROIC/WACC0.08

Cap/Depr(3y)260.42%

Cap/Depr(5y)209.27%

Cap/Sales(3y)18.57%

Cap/Sales(5y)15.29%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-219.63%

EPS 3Y-64%

EPS 5YN/A

EPS Q2Q%-268.75%

EPS Next Y-340.43%

EPS Next 2Y-74.62%

EPS Next 3Y-44.51%

EPS Next 5YN/A

Revenue 1Y (TTM)-6.91%

Revenue growth 3Y-7.18%

Revenue growth 5Y-4.39%

Sales Q2Q%-3.31%

Revenue Next Year-0.95%

Revenue Next 2Y5.78%

Revenue Next 3Y7%

Revenue Next 5YN/A

EBIT growth 1Y-51.75%

EBIT growth 3Y-50.34%

EBIT growth 5Y-22.39%

EBIT Next Year8.9%

EBIT Next 3Y30.86%

EBIT Next 5YN/A

FCF growth 1Y-850%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-121.46%

OCF growth 3YN/A

OCF growth 5YN/A

ERAMET / ER7.DE FAQ

What is the fundamental rating for ER7 stock?

ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.

Can you provide the valuation status for ERAMET?

ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.

What is the profitability of ER7 stock?

ERAMET (ER7.DE) has a profitability rating of 3 / 10.

Can you provide the financial health for ER7 stock?

The financial health rating of ERAMET (ER7.DE) is 1 / 10.

How sustainable is the dividend of ERAMET (ER7.DE) stock?

The dividend rating of ERAMET (ER7.DE) is 2 / 10 and the dividend payout ratio is -44.33%.

ERAMET (ER7.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

ERAMET / ER7.DE FAQ

What is the fundamental rating for ER7 stock?

Can you provide the valuation status for ERAMET?

What is the profitability of ER7 stock?

Can you provide the financial health for ER7 stock?

How sustainable is the dividend of ERAMET (ER7.DE) stock?